Deals this week: Trianni, ANI Pharma, Merus Labs
Trianni and Evotec AG have entered a co-development agreement to develop Evotec's existing drug discovery platforms, as well as new projects. The agreement enables Evotec to gain access to the Trianni mice platform, a therapeutic antibody discovery platform.
ANI Pharma, an integrated speciality pharmaceutical company, has entered a distribution and supply agreement with branded and generic pharmaceuticals supplier Aspen Global Incorporated, to commercialise the latter's hydroxyprogesterone caproate (HPC) injection in the US market and also to strengthen its product line. Pursuant to the agreement, Aspen will supply the finished dose form of the injection and ANI Pharma will be responsible for the marketing and distribution of the same in the US.Merus Labs has issued 14,250,000 of its shares by exercising its outstanding special warrants to raise funds amounting to $21m. The company has invested the funds to acquire the rights to Sanofi S.A.'s pharmaceutical products including Surgestone®, Provames®, Speciafoldine® and Tredemine®.Teleflex plans to repay its debts under revolving credit facility, through the funds raised from public offering of its 4.875% senior notes. The company has raised gross proceeds of $400m through the placement of its notes, due on 1 June 2026. J.P.Morgan Securities and Merrill Lynch, Pierce Fenner & Smith and Barclays Capital acted as the joint bookrunning managers, while Credit Suisse Securities, Goldman Sachs & Co, HSBC Securities US Bancorp Investments and Wells Fargo Securities acted as co-managers for the offering.Caribou Biosciences plans to expand its industry-leading CRISPR gene editing technology platform and develop its efforts in application areas of agriculture, therapeutics, biological research and industrial biotechnology by using the funds raised in a series B financing round. The company has raised $30m through the financing round, which was led by Anterra Capital, Heritage Group, Maverick Capital, Pontifax Global food and Agriculture Technologies Fund, along with F-Prime Capital, Novartis AG, Mission Bay Capital and 5 Prime Ventures.20 May 2016
http://www.pharmaceutical-technology.com/
